135 related articles for article (PubMed ID: 30610005)
21. The expression of transforming growth factor-alpha in cirrhosis, dysplastic nodules, and hepatocellular carcinoma: an immunohistochemical study of 70 cases.
Yeh MM; Larson AM; Campbell JS; Fausto N; Rulyak SJ; Swanson PE
Am J Surg Pathol; 2007 May; 31(5):681-9. PubMed ID: 17460450
[TBL] [Abstract][Full Text] [Related]
22. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules.
Park YN; Kojiro M; Di Tommaso L; Dhillon AP; Kondo F; Nakano M; Sakamoto M; Theise ND; Roncalli M
Cancer; 2007 Mar; 109(5):915-23. PubMed ID: 17279586
[TBL] [Abstract][Full Text] [Related]
23. The cytological characteristics of small cell change of dysplasia in small hepatic nodules.
Chang O; Yano Y; Masuzawa A; Fukushima N; Teramura K; Hayashi Y
Oncol Rep; 2010 May; 23(5):1229-32. PubMed ID: 20372834
[TBL] [Abstract][Full Text] [Related]
24. Dysplastic nodules with glypican-3 positive immunostaining: a risk for early hepatocellular carcinoma.
Gong L; Wei LX; Ren P; Zhang WD; Liu XY; Han XJ; Yao L; Zhu SJ; Lan M; Li YH; Zhang W
PLoS One; 2014; 9(1):e87120. PubMed ID: 24498024
[TBL] [Abstract][Full Text] [Related]
25. Increased ubiquitin immunoreactivity in hepatocellular carcinomas and precancerous lesions of the liver.
Osada T; Sakamoto M; Nishibori H; Iwaya K; Matsuno Y; Muto T; Hirohashi S
J Hepatol; 1997 Jun; 26(6):1266-73. PubMed ID: 9210613
[TBL] [Abstract][Full Text] [Related]
26. EZH2 protein: a promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies.
Cai MY; Tong ZT; Zheng F; Liao YJ; Wang Y; Rao HL; Chen YC; Wu QL; Liu YH; Guan XY; Lin MC; Zeng YX; Kung HF; Xie D
Gut; 2011 Jul; 60(7):967-76. PubMed ID: 21330577
[TBL] [Abstract][Full Text] [Related]
27. The clinicopathological significance of heat shock protein 70 and glutamine synthetase expression in hepatocellular carcinoma.
Shin E; Ryu HS; Kim SH; Jung H; Jang JJ; Lee K
J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):544-50. PubMed ID: 21234611
[TBL] [Abstract][Full Text] [Related]
28. Cytokeratin19 positive hepatocellular carcinoma is associated with increased peritumoral ductular reaction.
Cai X; Feng L; Liu H; Xu M; Qu Y; Wan X; Gao C; Lu L
Ann Hepatol; 2016; 15(3):386-93. PubMed ID: 27049492
[TBL] [Abstract][Full Text] [Related]
29. [Dysplastic nodule of liver versus early hepatocellular carcinoma: a clinicopathologic and prognostic study].
Chen L; Tan Y; Zeng H; Hou Y; Xu J; Zhao J; Ji Y
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):301-6. PubMed ID: 25030861
[TBL] [Abstract][Full Text] [Related]
30. [Hepatocarcinogenesis in human liver].
Nagy P; László V; Schaff Z
Magy Onkol; 2006; 50(2):107-13. PubMed ID: 16888673
[TBL] [Abstract][Full Text] [Related]
31. Histopathology of hepatocellular carcinoma.
Schlageter M; Terracciano LM; D'Angelo S; Sorrentino P
World J Gastroenterol; 2014 Nov; 20(43):15955-64. PubMed ID: 25473149
[TBL] [Abstract][Full Text] [Related]
32. [How to improve the histopathological diagnosis of hepatocellular carcinoma in daily practice?].
Honsová E; Lodererová A
Cesk Patol; 2011 Apr; 47(2):40-3. PubMed ID: 21604432
[TBL] [Abstract][Full Text] [Related]
33. A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values.
Jin GZ; Dong H; Yu WL; Li Y; Lu XY; Yu H; Xian ZH; Dong W; Liu YK; Cong WM; Wu MC
BMC Cancer; 2013 Mar; 13():161. PubMed ID: 23537217
[TBL] [Abstract][Full Text] [Related]
34. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis.
Roskams T; Kojiro M
Semin Liver Dis; 2010 Feb; 30(1):17-25. PubMed ID: 20175030
[TBL] [Abstract][Full Text] [Related]
35. Immunostaining of glutamine synthetase is a sensitive and specific marker for diagnosing focal nodular hyperplasia in needle biopsy.
Tsai JH; Jeng YM; Pan CC; Lu SW; Kuo YJ
Pathology; 2012 Dec; 44(7):605-10. PubMed ID: 22990279
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of Genomic, Epigenomic, and Transcriptomic Aberrations during Stepwise Hepatocarcinogenesis.
Jee BA; Choi JH; Rhee H; Yoon S; Kwon SM; Nahm JH; Yoo JE; Jeon Y; Choi GH; Woo HG; Park YN
Cancer Res; 2019 Nov; 79(21):5500-5512. PubMed ID: 31506333
[TBL] [Abstract][Full Text] [Related]
37. Facing the enigma of the vascular network in hepatocellular carcinomas in cirrhotic and non-cirrhotic livers.
Vasuri F; Fittipaldi S; Giunchi F; Monica M; Ravaioli M; Degiovanni A; Bonora S; Golfieri R; Bolondi L; Grigioni WF; Pasquinelli G; D'Errico-Grigioni A
J Clin Pathol; 2016 Feb; 69(2):102-8. PubMed ID: 26243063
[TBL] [Abstract][Full Text] [Related]
38. Glypican-3 is a potential prognostic biomarker for hepatocellular carcinoma after curative resection.
Fu SJ; Qi CY; Xiao WK; Li SQ; Peng BG; Liang LJ
Surgery; 2013 Sep; 154(3):536-44. PubMed ID: 23601901
[TBL] [Abstract][Full Text] [Related]
39. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study.
Frachon S; Gouysse G; Dumortier J; Couvelard A; Nejjari M; Mion F; Berger F; Paliard P; Boillot O; Scoazec JY
J Hepatol; 2001 Jun; 34(6):850-7. PubMed ID: 11451168
[TBL] [Abstract][Full Text] [Related]
40. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
